Qilu Pharmaceutical Co., Ltd.
齊魯製藥有限公司
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-09-03 | InvaGen Pharmaceuticals Inc.; Cipla USA Inc. (commercialization) | QL2107 / pembrolizumab biosimilar | Not disclosed | Not disclosed | Not disclosed | In development; regulatory approval required |